A new direction for breast cancer therapy
Triple-negative breast cancer has the worst prognosis of the breast cancer subtypes. Aggressive forms of this cancer show elevated signaling through the transcription factor MYC,
Triple-negative breast cancer has the worst prognosis of the breast cancer subtypes. Aggressive forms of this cancer show elevated signaling through the transcription factor MYC,
A team of Swiss drug developers has designed a novel drug that cures breast cancer by completely blocking the activity of the surface receptor HER2
A study of a specific long noncoding RNA in a mouse model of breast cancer shows that knockdown of its expression suppresses metastasis.
A piece of noncoding DNA helps prevents cells from turning cancerous, and does so via two mechanisms. The noncoding DNA, which is called GNG12-ASI, acts
A drug, tetrathiomolybdate (TM), which mops up copper in the body and that had already failed in a series of previous cancer clinical trials, is
Australian researchers have found that so-called ‘triple-negative breast cancers’1 are two distinct diseases that likely originate from different cell types. This helps explain why survival
A new analysis led by researchers at the American Cancer Society in collaboration with the International Agency for Research on Cancer (IARC) finds lung cancer
A key aspect of cancer metastases is the tendency for specific cancer cells to home to defined subsets of secondary organs. Despite these known tendencies,
Estrogen is so intimately involved in breast cancer that drugs which disrupt the hormone’s actions have become frontline treatments for the disease. These so-called “hormonal
More and more, the first stop for a woman newly diagnosed with breast cancer is the chemotherapy ward rather than the operating room. That’s because
Recently, we gave readers the opportunity to share their opinions on mammography screening in Clinical Decisions, an interactive feature in which experts discuss a controversial
Nature (2012); Doi: 10.1038/nature10730. C. Ross-Innes, et al. “Differential oestrogen receptor binding is associated with clinical outcome in breast cancer”. A new study shows that
PLoS Biology, 2011; 9 (11): e1001199 DOI: 10.1371/journal.pbio.1001199 Maxwell CA, Benítez J, Gómez-Baldó L, Osorio A, Bonifaci N, et al. “Interplay between BRCA1 and RHAMM
Clinical Cancer Research, 2011. Doi: 10.1158/1078-0432. CCR-10-2887. Rafal Zielinski, Ilya Lyakhov, Moinuddin Hassan, Monika Kuban, Kimberly Shafer-Weaver, Amir Gandjbakhche, and Jacek Capala. “HER2-Affitoxin: A Potent Therapeutic Agent
Clinical Cancer Research, 2011. Doi: 10.1158/1078-0432. CCR-10-2887. Rafal Zielinski, Ilya Lyakhov, Moinuddin Hassan, Monika Kuban, Kimberly Shafer-Weaver, Amir Gandjbakhche, and Jacek Capala. “HER2-Affitoxin: A Potent Therapeutic Agent
Clinical Cancer Research, 2011. Doi: 10.1158/1078-0432. CCR-10-2887. Rafal Zielinski, Ilya Lyakhov, Moinuddin Hassan, Monika Kuban, Kimberly Shafer-Weaver, Amir Gandjbakhche, and Jacek Capala. “HER2-Affitoxin: A Potent Therapeutic Agent
An FDA panel voted on June 29 that bevacizumab (Avastin ®) in combination with paclitaxel should no longer be approved for treatment of metastatic HER2-negative
An FDA panel voted on June 29 that bevacizumab (Avastin ®) in combination with paclitaxel should no longer be approved for treatment of metastatic HER2-negative
Created by ePubSystems. Contact Us for similar site for your university or institute.